Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays

Biochemical Pharmacology

Volumn 96, Issue 2, 2015, Pages 107-118

  Ramos Molina, Bruno ^a   Lick, Adam N ^a   Blanco, Elias H ^a   Posada Salgado, J Alejandro ^b   Martinez Mayorga, Karina ^b   Johnson, Alan T ^c   Jiao, Guan Sheng ^c   Lindberg, Iris ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c HAWAII BIOTECH INC   (United States)

Author keywords

Cell based assays; Furin; Furin inhibitors; Proprotein convertases; Protease

Indexed keywords

1,1' [4 ((2,4 DIGUANIDINO 5 (4 GUANIDINOPHENOXY)CYCLOHEXYL)OXY) 1,3 PHENYLENE]DIGUANIDINE; 1,1' [4,6 BIS(4 GUANIDINOPHENOXY)CYCLOHEXANE 1,3 DIYL]DIGUANIDINE; 1,3 BIS(2,4 DIGUANIDINOPHENOXY) BENZENE; 1,3 BIS(2,4 DIGUANIDINOPHENOXY)BENZENE; 1,3 BIS(2,4 DIGUANIDINOPHENOXY)PROPANE; 1,3 BIS(4 GUANIDINOPHENOXY)BENZENE; 1,3 BIS(4 GUANIDINOPHENOXY)PROPANE; 2,5 DIDEOXYSTREPTAMINE DERIVATIVE; CIS 1,3 BIS(2,4 DIGUANIDINOPHENOXY)CYCLOHEXANE; CIS 1,3 BIS(4 GUANIDINOPHENOXY)CYCLOHEXANE; ETHER DERIVATIVE; FURIN; GUANIDINE DERIVATIVE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; 2,5-DIDEOXYSTREPTAMINE; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; HEXOSAMINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROTECTION; CELL SURFACE; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; EX VIVO STUDY; GOLGI COMPLEX; HYDROGEN BOND; HYDROGENATION; IN VITRO STUDY; MIGRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL MEMBRANE; CELL MOTION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DRUG EFFECTS; ENZYMOLOGY; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOUSE; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; CELL MEMBRANE; CELL MOVEMENT; CELL SURVIVAL; CRICETULUS; FURIN; GUANIDINES; HEXOSAMINES; HUMANS; INTRACELLULAR SPACE; MICE; MODELS, MOLECULAR; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84930576034     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.05.008     Document Type: Article

References (67)

1. K. Nakayama Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins Biochem. J. 327 Pt 3 1997 625 635
2. N.G. Seidah The proprotein convertases, 20 years later Methods Mol. Biol. 768 2011 23 57
3. S.S. Molloy, E.D. Anderson, F. Jean, and G. Thomas Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis Trends Cell Biol. 9 1999 28 35
4. G. Thomas Furin at the cutting edge: from protein traffic to embryogenesis and disease Nat. Rev. Mol. Cell Biol. 3 2002 753 766
5. A.J. Roebroek, L. Umans, I.G. Pauli, E.J. Robertson, F. van Leuven, and W.J. Van de Ven Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin Development 125 1998 4863 4876
6. A.J. Roebroek, N.A. Taylor, E. Louagie, I. Pauli, L. Smeijers, and A. Snellinx Limited redundancy of the proprotein convertase furin in mouse liver J. Biol. Chem. 279 2004 53442 53450
7. J.W. Creemers, and A.M. Khatib Knock-out mouse models of proprotein convertases: unique functions or redundancy Front. Biosci. 13 2008 4960 4971
8. S. Takahashi, K. Kasai, K. Hatsuzawa, N. Kitamura, Y. Misumi, and Y. Ikehara A mutation of furin causes the lack of precursor-processing activity in human colon carcinoma LoVo cells Biochem. Biophys. Res. Commun. 195 1993 1019 1026
9. B.D. Bennett, P. Denis, M. Haniu, D.B. Teplow, S. Kahn, and J.C. Louis A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's β-secretase J. Biol. Chem. 275 2000 37712 37717
10. E.C. Arner Aggrecanase-mediated cartilage degradation Curr. Opin. Pharmacol. 2 2002 322 329
11. P. Stawowy, H. Meyborg, D. Stibenz, N. Borges Pereira Stawowy, M. Roser, and U. Thanabalasingam Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis Circulation 111 2005 2820 2827
12. D.E. Bassi, J. Fu, R. Lopez De Cicco, and A.J. Klein-Szanto Proprotein convertases: master switches in the regulation of tumor growth and progression Mol. Carcinog. 44 2005 151 161
13. M. Mbikay, F. Sirois, J. Yao, N.G. Seidah, and M. Chretien Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours Br. J. Cancer 75 1997 1509 1514
14. D.E. Bassi, H. Mahloogi, and A.J. Klein-Szanto The proprotein convertases furin and PACE4 play a significant role in tumor progression Mol. Carcinog. 28 2000 63 69
15. J. Fu, D.E. Bassi, J. Zhang, T. Li, E. Nicolas, and A.J. Klein-Szanto Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth Neoplasia 14 2012 271 282
16. D.E. Bassi, H. Mahloogi, L. Al-Saleem, R. Lopez De Cicco, J.A. Ridge, and A.J. Klein-Szanto Elevated furin expression in aggressive human head and neck tumors and tumor cell lines Mol. Carcinog. 31 2001 224 232
17. A.M. Khatib, G. Siegfried, A. Prat, J. Luis, M. Chrétien, and P. Metrakos Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions J. Biol. Chem. 27 2001 30686 30693
18. V.M. Gordon, K.R. Klimpel, N. Arora, M.A. Henderson, and S.H. Leppla Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases Infect. Immun. 63 1995 82 87
19. O. Garred, B. van Deurs, and K. Sandvig Furin-induced cleavage and activation of shiga toxin J. Biol. Chem. 270 1995 10817 10821
20. A. Basak, M. Zhong, J.S. Munzer, M. Chretien, and N.G. Seidah Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides Biochem. J. 353 2001 537 545
21. M. Moulard, and E. Decroly Maturation of HIV envelope glycoprotein precursors by cellular endoproteases Biochim. Biophys. Acta 1469 2000 121 132
22. V. Volchkov, H. Feldmann, V.A. Volchkova, and H.D. Klenk Processing of the Ebola virus glycoprotein by proprotein convertase furin Proc. Natl. Acad. Sci. U. S. A. 95 1998 5762 5767
23. T. Komiyama, J.A. Swanson, and R.S. Fuller Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine Antimicrob. Agents Chemother. 49 9 2005 3875 3882
24. S. Ozden, M. Lucas-Hourani, P.E. Ceccaldi, A. Basak, M. Valentine, and S. Benjannet Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein J. Biol. Chem. 283 2008 21899 21908
25. G.L. Becker, Y. Lu, K. Hardes, B. Strehlow, C. Levesque, and I. Lindberg Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases J. Biol. Chem. 287 2012 21992 22003
26. J.M. Coppola, M.S. Bhojani, B.D. Ross, and A. Rehemtulla A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness Neoplasia 10 2008 363 370
27. D. Bassi, R. Lopez de Cicco, H. Mahloogi, S. Zucker, G. Thomas, and J. Klein-Szanto Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells Proc. Natl. Acad. Sci. U. S. A. 98 2001 10326 10331
28. F. D'Anjou, F. Couture, R. Desjardins, and R. Day Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells Methods Mol. Biol. 1103 2014 67 82
29. R. Longuespee, F. Couture, C. Levesque, A. Kwiatkowska, R. Desjardins, and S. Gagnon Implications of proprotein convertases in ovarian cancer cell proliferation and tumor progression: insights for PACE4 as a therapeutic target Transl. Oncol. 7 2014 410 419
30. M. Fugere, and R. Day Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition Trends Pharmacol. Sci. 26 2005 294 301
31. G.S. Jiao, L. Cregar, J. Wang, S.Z. Millis, C. Tang, and S. O'Malley Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine Proc. Natl. Acad. Sci. U. S. A. 103 2006 19707 19712
32. M.M. Kacprzak, J.R. Peinado, M.E. Than, J. Appel, S. Henrich, and G. Lipkind Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-d-arginine J. Biol. Chem. 279 2004 36788 36794
33. M. Vivoli, T.R. Caulfield, K. Martinez-Mayorga, A.T. Johnson, G.S. Jiao, and I. Lindberg Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives Mol. Pharmacol. 81 2012 440 454
34. E. Apletalina, J. Appel, N.S. Lamango, R.A. Houghten, and I. Lindberg Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library J. Biol. Chem. 273 1998 26589 26595
35. A. Cameron, Y. Fortenberry, and I. Lindberg The SAAS granin exhibits structural and functional homology to 7B2 and contains a highly potent hexapeptide inhibitor of PC1 FEBS Lett. 473 2000 135 138
36. J.M. Coppola, C.A. Hamilton, M.S. Bhojani, M.J. Larsen, B.D. Ross, and A. Rehemtulla Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity Anal. Biochem. 364 2007 19 29
37. S.O. Dahms, K. Hardes, G.L. Becker, T. Steinmetzer, H. Brandstetter, and M.E. Than X-ray structures of human furin in complex with competitive inhibitors ACS Chem. Biol. 9 2014 1113 1118
38. H.J. Motulsky, and A. Christopoulos Fitting Models to Biological Data using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting 2003 GraphPad Software Inc. San Diego, CA
39. F. Lopez-Vallejo, and K. Martinez-Mayorga Furin inhibitors: importance of the positive formal charge and beyond Bioorg. Med. Chem. 20 2012 4462 4471
40. F. Jean, K. Stella, L. Thomas, G. Liu, Y. Xiang, and A.J. Reason Alpha1-antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent Proc. Natl. Acad. Sci. U. S. A. 95 1998 7293 7298
41. G.S. Jiao, L. Cregar, M.E. Goldman, S.Z. Millis, and C. Tang Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors Bioorg. Med. Chem. Lett. 16 2006 1527 1531
42. J.R. Peinado, M.M. Kacprzak, S.H. Leppla, and I. Lindberg Cross-inhibition between furin and lethal factor inhibitors Biochem. Biophys. Res. Commun. 321 2004 601 605
43. T. Komiyama, J.M. Coppola, M.J. Larsen, M.E. van Dort, B.D. Ross, and R. Day Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules J. Biol. Chem. 284 2009 15729 15738
44. N.G. Seidah, and A. Prat The biology and therapeutic targeting of the proprotein convertases Nat. Rev. Drug Discov. 11 2012 367 383
45. F. Couture, F. D'Anjou, and R. Day On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications Biomol. Concepts 2 2011 421 438
46. R.E. Page, A.J. Klein-Szanto, S. Litwin, E. Nicolas, R. Al-Jumaily, P. Alexander, and A.K. Godwin Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer Cell Oncol. 29 2007 289 299
47. M. Cheng, P.H. Watson, J.A. Paterson, N. Seidah, M. Chretien, and R.P. Shiu Pro-protein convertase gene expression in human breast cancer Int. J. Cancer 71 1997 966 971
48. J. Mercapide, R. Lopez De Cicco, D.E. Bassi, J.S. Castresana, G. Thomas, and A.J. Klein-Szanto Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness Clin. Cancer Res. 8 2002 1740 1746
49. J.A. Schalken, A.J. Roebroek, P.P. Oomen, S.S. Wagenaar, F.M. Debruyne, and H.P. Bloemers fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas J. Clin. Invest. 80 1987 1545 1549
50. G. Siegfried, A. Basak, J.A. Cromlish, S. Benjannet, J. Marcinkiewicz, and M. Chretien The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis J. Clin. Invest. 111 2003 1723 1732
51. B.K. McColl, K. Paavonen, T. Karnezis, N.C. Harris, N. Davydova, and J. Rothacker Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2 FASEB J. 21 2007 1088 1098
52. H. Sato, T.T. Kinoshita, K. Nakayama, and M. Seiki Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2 FEBS Lett. 393 1996 101 104
53. J. Cao, A. Rehemtulla, W. Bahou, and S. Zucker Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain J. Biol. Chem. 271 1996 30174 30180
54. M. Mazzone, M. Baldassarre, G. Beznoussenko, G. Giacchetti, J. Cao, and S. Zucker Intracellular processing and activation of membrane type 1 matrix metalloprotease depends on its partitioning into lipid domains J. Cell Sci. 117 2004 6275 6287
55. I. Yana, and S.J. Weiss Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases Mol. Biol. Cell 11 2000 2387 2401
56. M. Seiki Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion Cancer Lett. 194 2003 1 11
57. D.E. Bassi, J. Zhang, J. Cenna, S. Litwin, E. Cukierman, and A.J. Klein-Szanto Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis Neoplasia 12 2010 516 526
58. A.G. Remacle, K. Gawlik, V.S. Golubkov, G.W. Cadwell, R.C. Liddington, and P. Cieplak Selective and potent furin inhibitors protect cells from anthrax without significant toxicity Int. J. Biochem. Cell Biol. 42 2010 987 995
59. H. Gagnon, S. Beauchemin, A. Kwiatkowska, F. Couture, F. D'Anjou, and C. Levesque Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin J. Med. Chem. 57 2014 29 41
60. A. Kwiatkowska, F. Couture, C. Levesque, K. Ly, R. Desjardins, and S. Beauchemin Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor J. Med. Chem. 57 2014 98 109
61. G.L. Becker, F. Sielaff, M.E. Than, I. Lindberg, S. Routhier, and R. Day Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics J. Med. Chem. 53 2010 1067 1075
62. M.S. Sarac, J.R. Peinado, S.H. Leppla, and I. Lindberg Protection against anthrax toxemia by hexa-d-arginine in vitro and in vivo Infect. Immun. 72 2004 602 605
63. S.S. Molloy, P.A. Bresnahan, S.H. Leppla, K.R. Klimpel, and G. Thomas Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen J. Biol. Chem. 267 1992 16396 16402
64. M.S. Sarac, A. Cameron, and I. Lindberg The furin inhibitor hexa-d-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo Infect. Immun. 70 2002 7136 7139
65. A. Cameron, J. Appel, R.A. Houghten, and I. Lindberg Polyarginines are potent furin inhibitors J. Biol. Chem. 275 2000 36741 36749
66. M. Fugere, J. Appel, R.A. Houghten, I. Lindberg, and R. Day Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences Mol. Pharmacol. 71 2007 323 332
67. P. Karicherla, and J.A. Hobden Nona-d-arginine therapy for Pseudomonas aeruginosa keratitis Invest. Ophthalmol. Vis. Sci. 50 2009 256 262